Wells Fargo Maintains Equal-Weight on Amgen, Raises Price Target to $435
Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $400 to $435.
Stocks · News reference
AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophilic esophagitis (EoE) treatment.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Want $500 a Month in Passive Income? Start With This Brilliant Dividend ETF.
The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as an effective vehicle for generating sustainable passive income through dividends. With a 3.2% yield and a history of increasing annual dividends since 2011, investors would need approximately $187,500 invested to generate $500 monthly in dividend income. The fund focuses on high-quality dividend-paying stocks and has delivered 13.4% annual returns since inception.
If the AI Boom Slows Down, History Says This Is the Smartest Way to Protect Your Long-Term Portfolio
As concerns grow about a potential AI market slowdown due to inflation, rate hikes, and geopolitical tensions, investors should consider diversifying into dividend-focused ETFs like SCHD. The Schwab U.S. Dividend Equity ETF offers exposure to 100 stable, dividend-paying stocks across multiple sectors, providing a defensive hedge against AI stock volatility while delivering steady income and historical returns of 243% over the past decade.
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ
Fidelity's FHLC and Invesco's IBBQ offer different healthcare investment strategies. FHLC provides broad exposure to 365 healthcare holdings with a lower 0.08% expense ratio and 1.2% dividend yield, while IBBQ focuses on biotech with higher volatility, delivering 56.4% 1-year returns but experiencing a 37.9% maximum drawdown. The choice depends on investor risk tolerance and diversification preferences.
FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation; Authorizes Guardant360 CDx Assay As Companion Diagnostic For Breast Cancer
https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca's stock has fallen 19.5% in six months due to several clinical and pipeline setbacks, including failed studies for Wainua and Ultomiris, and FDA delays for camizestrant. However, the company maintains solid fundamentals with 16 blockbuster drugs, 15% oncology sales growth, and targets $80 billion in revenues by 2030 with 20 new medicines planned. Despite headwinds from patent expirations and China market uncertainties, analysts recommend staying invested given growth prospects.